Dyne Therapeutics, Inc.
DYN
$10.02
-$1.81-15.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.48M | 56.02M | 50.18M | 48.09M | 31.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 343.89M | 314.47M | 271.08M | 265.85M | 242.16M |
| Operating Income | -343.89M | -314.47M | -271.08M | -265.85M | -242.16M |
| Income Before Tax | -317.42M | -294.51M | -257.60M | -257.40M | -235.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -317.42 | -294.51 | -257.60 | -257.40 | -235.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -317.42M | -294.51M | -257.60M | -257.40M | -235.94M |
| EBIT | -343.89M | -314.47M | -271.08M | -265.85M | -242.16M |
| EBITDA | -342.21M | -312.84M | -269.47M | -264.21M | -240.49M |
| EPS Basic | -3.35 | -3.56 | -3.58 | -3.97 | -3.94 |
| Normalized Basic EPS | -2.10 | -2.23 | -2.24 | -2.48 | -2.46 |
| EPS Diluted | -3.35 | -3.56 | -3.58 | -3.97 | -3.94 |
| Normalized Diluted EPS | -2.10 | -2.23 | -2.24 | -2.48 | -2.46 |
| Average Basic Shares Outstanding | 376.42M | 335.83M | 296.05M | 263.38M | 238.66M |
| Average Diluted Shares Outstanding | 376.42M | 335.83M | 296.05M | 263.38M | 238.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |